New hope for myelofibrosis: drug combo targets tough cases
NCT ID NCT06909136
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (WJ01024) combined with an existing drug (ruxolitinib) in 33 adults with intermediate- or high-risk myelofibrosis whose spleen is enlarged and who didn't respond well to or couldn't tolerate previous JAK inhibitor treatments. The goal is to see if the combination is safe and can shrink the spleen and reduce symptoms. The trial has two phases: first finding the right dose, then testing how well it works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- WJ01024 tablets combined with ruxolitinib tablets
- What this could lead to
- If successful, this combination could offer a new treatment option for people with myelofibrosis who haven't responded well to or can't tolerate current JAK inhibitor therapy.
- What could go wrong
- This is an early-phase trial with only 33 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink the spleen or improve symptoms significantly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERMEDIATE- AND HIGH-RISK MYELOFIBROSIS (MF) PATIENTS WITH SPLENOMEGALY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital
Zhengzhou, Zhengzhou, 450000, China